Nuvo Announces Co-Operative Drug Development Project with Germany's Fraunhofer Institute
News Sep 02, 2009
Nuvo Research Inc. has announced a co-operative drug development project with the Fraunhofer Institute for Cell Therapy and Immunology IZI in Leipzig, Germany for the preclinical and clinical development of WF10 as a potential treatment for Allergic Rhinitis.
The Development Bank of Saxony in Germany (SAB) announced in late August that it will provide financial support for this co-operative project that will be conducted in Leipzig, Germany through Nuvo Research GmbH, a Nuvo subsidiary. Discussions are ongoing with SAB about expanding its financial support to include preclinical and clinical development of WF10 as a potential treatment for Rheumatoid Arthritis.
“Teaming up with exceptional partners like the Fraunhofer Institute and the Development Bank of Saxony should accelerate WF10’s preclinical and clinical development,” said Henrich Guntermann, President and Chief Executive Officer of Nuvo Research. “This partnership provides Nuvo with financial support that will allow us to more effectively deploy our own resources to develop WF10 as a needed treatment for patients who suffer from allergies and related asthma.”
The immune system provides an essential defense to micro organisms, cancer and substances it sees as foreign and potentially harmful. WF10 focuses on supporting the immune system by targeting the macrophage, a type of white blood cell that coordinates much of the immune system, to regulate normal immune function.
In conditions such as Allergic Rhinitis, the body’s immune system inappropriately responds to the presence of foreign allergens. Research suggests that in some cases, WF10 may rebalance improperly functioning immune systems.
New Chemical Synthesis Process: Synergy of Two Catalysts in One FlaskNews
Researchers report the one-step synthesis of a ketone from an aldehyde by the combination of thiazolium N-heterocyclic carbene and palladium/bisphosphine catalysts in one flask. The two catalysts function in a synergistic manner. This study is expected to lead to new synthesis processes of precursor compounds for medications.READ MORE
Synthesis of Drug-Like Molecules Simplified Using New Cross-Coupling MethodNews
Researchers have designed a new molecule-building method. The technique, described recently in the journal Science, paves the way toward other new chemical reactions and facilitates the synthesis of pharmaceutically-relevant molecules.READ MORE
Domainex Appoints Dr Bodo Spori as Head of Business Development for EuropeNews
Domainex Ltd, a privately-owned drug discovery services company, is pleased to announce the appointment of Dr Bodo Spori as Head of Business Development for Europe.READ MORE
Comments | 0 ADD COMMENT
World Congress on Advanced Pharmacy and Clinical Research
Jul 16 - Jul 17, 2018